News Decision-Making Support

NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform

The National Comprehensive Cancer Network (NCCN) has entered into a licensing agreement with OpenEvidence that would make the NCCN Clinical Practice Guidelines in Oncology accessible through OpenEvidence's AI–powered medical platform.

November 07, 2025 By ASCO AI Staff 2 min read
Share
Objective:

To enhance access to NCCN Clinical Practice Guidelines in Oncology through OpenEvidence's AI-powered platform.

Key Findings:
  • The integration will facilitate faster access to trusted cancer care recommendations.
  • OpenEvidence is already utilized by hundreds of thousands of U.S. physicians for clinical information.
  • NCCN guidelines are recognized as the gold standard for oncology practice globally.
Interpretation:

This collaboration aims to leverage AI to improve the accessibility and application of expert oncology guidelines in clinical settings.

Limitations:
  • The article does not specify the timeline for the integration process.
  • Potential challenges in ensuring the accuracy and reliability of AI-generated recommendations are not addressed.
Conclusion:

The partnership between NCCN and OpenEvidence represents a significant advancement in making oncology guidelines more accessible and actionable for healthcare providers.

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content